Combination-based regimens containing CD38 antibodies are currently the subject of ongoing clinical trials in AML (NCT03537599), ALL (NCT03860844), and CLL (NCT04230304). The gene discussed is CD38; the disease is B-cell chronic lymphocytic leukemia.